Who should not take eflornithine tablets?

Eflornithine tablets (eflornithine), as an ornithine decarboxylase (ODC) inhibitor, are mainly used to treat certain types of neuroblastoma and can also be used for diseases such as advanced African trypanosomiasis. Although the drug has shown positive effects in some difficult-to-treat cancers, not all patients are suitable for it.

First, use should be avoided entirely in individuals with a known allergy to eflornithine or ingredients in its formulations to prevent the development of severe allergic reactions, including rash, bronchospasm, and even anaphylactic shock.

Secondly, patients with severe liver and kidney damage should use the drug with caution. Eflornithine is mainly metabolized and excreted by the kidneys. If the kidneys are insufficient, the drug is easy to accumulate in the body, which may cause toxic and side effects, especially blood system toxicity and nervous system side effects.

In addition, whether to use eflornithine during pregnancy or lactation needs to be decided under strict evaluation by a doctor, as it may have potential effects on the fetus or infant and there is currently a lack of sufficient human safety data. Although children are one of the suitable groups for this drug, the dosage must be accurately adjusted according to body weight when used, and adverse reaction monitoring must be strengthened.

At the same time, for patients treated with other immunosuppressive or cytotoxic drugs, such as radiotherapy and chemotherapy, the additive toxicity of eflornithine cannot be ignored. Special groups of people, such as the elderly, should be more careful in assessing risks due to their weakened metabolic capacity.

In addition, some patients with epilepsy or other neurological diseases need to be concerned that eflornithine may aggravate neurotoxicity when taking it. To sum up, although eflornithine brings therapeutic hope to some severely ill patients, the drug users should be carefully selected and an individualized medication strategy should be formulated under the evaluation of professional doctors to ensure a balance between therapeutic effect and safety.

Reference materials:https://www.drugs.com/mtm/eflornithine.html